Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Mymetics:NIH Plan to Test HIV-AIDS vaccine...

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Mymetics:NIH Plan to Test HIV-AIDS vaccine...

9 Posts
| Omlaag ↓
  1. [verwijderd] 10 maart 2006 19:55
    Mymetics' HIV-AIDS prophylactic vaccine candidate program combines the Company's HIV-1 gp41-based immunogen expertise with virosome technology developed by Pevion Biotech AG (Switzerland), a spin-off from Berna AG and Bachem AG. Virosome-based vaccines are market-approved, stable lipidic structures that act as carriers for peptides or proteins toward which an immune protection is desired. Virosomes have a high safety profile with few side effects and have already been distributed by Pevion Biotech AG and administered to millions of people around the world.
    **********************

    Mymetics Announces NIH Plan to Test HIV-AIDS Vaccine Candidate in Non-Human Primate Model

    Friday March 10, 7:30 am ET

    Mymetics to Present Earlier-Stage Preclinical Results This Month at the Annual AIDS Keystone Meeting in Colorado

    NYON, Switzerland, March 10 /PRNewswire-FirstCall/ -- Mymetics Corporation (OTC: MYMX - News) announced today that the National Institutes of Health (NIH) has agreed to initiate testing of the Company's proprietary HIV-AIDS mucosal prophylactic vaccine candidate. The preclinical study will test Mymetics' vaccine in a non-human primate model. This study will take place in parallel to Mymetics' ongoing preclinical trial in another primate model. Mymetics' study was recently initiated in collaboration with the Cochin Institute (Paris, France), the Institute of Laboratory Animal Science of the Chinese Academy of Medical Sciences and the Faculty of Laboratory Animal Sciences of the Peking Union Medical College in Beijing (Republic of China).
    ADVERTISEMENT


    Mymetics also announced that the Company will present results of an earlier-stage preclinical study at the Keystone HIV Vaccines symposium being held from March 27 - April 2 in Keystone, Colorado. In this earlier study, Mymetics' vaccine elicited antibodies in the blood and other important anatomical compartments, such as internal mucosal surfaces, considered to be primary HIV entry sites. The mucosal antibodies showed high potency in vitro at inhibiting transcytosis of laboratory and primary HIV viruses from different HIV clades (strains), including those prevalent in Western countries and in Africa and parts of Asia. The Company will announce detailed results during the Keystone meeting.

    Dr. Sylvain Fleury, Ph.D., Mymetics' Chief Scientific Officer, commented, "We are extremely pleased that the NIH, an acknowledged world leader in supporting various vaccine research programs, has agreed to initiate their own preclinical study, qualifying our latest vaccine candidate as 'very promising [and worthy of] a thorough evaluation.' In the Company's concurrent trials, we will seek to confirm the results of the previous preclinical study demonstrating production of high levels of antibodies. If successful, we will then conduct a challenge study to determine the ability of these antibodies to protect against HIV in the primate models."

    Dr. Fleury continued, "The first results of the primate trials can be expected by the first quarter of 2007. Pending positive findings, we will then proceed to file with the FDA to begin pilot human clinical testing."

    Mymetics' HIV-AIDS prophylactic vaccine candidate program combines the Company's HIV-1 gp41-based immunogen expertise with virosome technology developed by Pevion Biotech AG (Switzerland), a spin-off from Berna AG and Bachem AG. Virosome-based vaccines are market-approved, stable lipidic structures that act as carriers for peptides or proteins toward which an immune protection is desired. Virosomes have a high safety profile with few side effects and have already been distributed by Pevion Biotech AG and administered to millions of people around the world.

    ABOUT MYMETICS

    Mymetics' research teams have made a series of important discoveries about how the body's immune system responds to HIV-1 (Human Immunodeficiency Virus type 1, the virus causing human AIDS).

    Our key discovery is a fundamental though subtle three-dimensional mimicry between the viral envelope glycoprotein gp41 of HIV-1 and the IL-2 cytokine (Interleukin-2) of the infected host. IL-2 is one of the most important messengers of the immune system. IL-2 helps to coordinate the immune response, in addition to being crucial for the generation of new T cells. This molecular mimicry between gp41 and IL-2 forms the basis of the company's platform technology.

    By understanding the precise dynamics of the virus's gp41 and the host's IL-2, Mymetics has been able to engineer gp41-derived antigens (proteins and peptides) capable of eliciting antibodies with strong potential for preventing infection by primary HIV-1 strains from various clades.

    Mymetics has also designed specific therapeutic molecules which have the potential to prevent and/or delay the disease. Equally important, these findings can be applied to other retroviruses-related diseases that involve similar mimicries, including certain oncoviruses often associated with human leukemia.

    Mymetics believes that successful protection against HIV-1 resides in the development of vaccines that will combine both cellular & humoral responses. However, to induce such protective responses, Mymetics strongly believes that it is crucial to prevent the potential induction of cross-reactivity toward self-proteins (ex. IL-2) after HIV vaccination for generating a good and long- lasting immune protection against HIV-1.

    Mymetics proposes an innovative vaccine by combining three important concepts:

    1- Minimal mimicry, which consists to remove in part or entirely the human homologies naturally present in some HIV proteins that serve as vaccine component. To achieve that objective, Mymetics intends to use the smallest engineered viral antigen sequence for limiting homologies with human proteins. Furthermore, it is easier to remove human homologies into a small viral protein because of their limited distribution. Our approach should significantly reduce the risk of developing potential autoimmunity on a long- term basis following vaccination;

    2- Focused immune response on relevant gp41 epitopes that may induce protective antibodies. Mymetics is developing vaccines that contain antigens expressing limited immunodominant regions, while immunodistractive regions have been removed or altered without affecting the immunogenicity of the antigen;

    3- Induction of mucosal and blood protection in different anatomical compartments. Induction of mucosal antibodies (anti-transcytosis) should block the early event of HIV translocation at the genito-reproductive and intestine tracts, thus preventing HIV entry and spreading in the body, while blood (systemic) antibodies will act on a later event that consists to prevent the infection of target cells (neutralizing antibodies).

    Mymetics pioneered an innovative efficient research strategy. Instead of incurring high fixed costs to maintain its own staff and research facilities, Mymetics organizes and manages a network of public and private best-in-class research teams, each of which has its own unique focus, while retaining all intellectual property rights on the joint research results.

    Mymetics was founded in 1990 near Lyon, France and was registered as a US (Delaware) public company in 2000. Since August 2003, its operations and research programs have been managed out of Switzerland (Nyon, near Geneva).
    biz.yahoo.com/prnews/060310/nyf033.ht...
  2. [verwijderd] 10 maart 2006 20:29
    Imo ook leuk, de "sales volumes 81% up" relatie met Acambis. Klein stukje uit pb-cijfers Acambis:

    Cambridge, UK and Cambridge, Massachusetts - 9 March 2006 - Acambis plc ("Acambis") (LSE: ACM, NASDAQ: ACAM) announces its results for the year ended 31 December 2005.

    VIVOTIF®
    Vivotif, the oral typhoid vaccine we sell in the US, had a strong year in 2005, with sales volumes 81% up over 2004. This was primarily as a result of our ability to capitalise on the competitor product's lack of availability for part of the year.
    sys-con.com/read/192643.htm
    *************************

    Vivotif®
    A live attenuated vaccine for oral immunization against typhoid fever, and the only such product against Salmonella typhi, the most virulent of the typhoid fever-causing bacteria.
    www.bernabiotech.com/products/

    In Crucell’s portfolio hepatitis B vaccines and a virosomal influenza vaccine play an important role. Travel vaccines are also marketed including the only available oral anti-typhoid vaccine.
    www.bernabiotech.com/news/news_full/i...
  4. [verwijderd] 12 maart 2006 08:51
    quote:

    flosz schreef:

    Imo ook leuk, de "sales volumes 81% up" relatie met Acambis. Klein stukje uit pb-cijfers Acambis:

    Cambridge, UK and Cambridge, Massachusetts - 9 March 2006 - Acambis plc ("Acambis") (LSE: ACM, NASDAQ: ACAM) announces its results for the year ended 31 December 2005.

    VIVOTIF®
    Vivotif, the oral typhoid vaccine we sell in the US, had a strong year in 2005, with sales volumes 81% up over 2004. This was primarily as a result of our ability to capitalise on the competitor product's lack of availability for part of the year.
    sys-con.com/read/192643.htm
    *************************

    Vivotif®
    A live attenuated vaccine for oral immunization against typhoid fever, and the only such product against Salmonella typhi, the most virulent of the typhoid fever-causing bacteria.
    www.bernabiotech.com/products/

    In Crucell’s portfolio hepatitis B vaccines and a virosomal influenza vaccine play an important role. Travel vaccines are also marketed including the only available oral anti-typhoid vaccine.
    www.bernabiotech.com/news/news_full/i...
    ***************************
    Gevonden:

    zeker - 17 jan 06, 20:41

    Hier het antwoord van Suykerbuyk:

    Berna Biotech A.G. levert aan haar voormalige dochteronderneming Berna Products Inc. Vivotif voor distributie in de VS.
    Dit bedrijf is destijds (2001) door Berna verkocht aan de minderheidsaandeelhouder.
    Die heeft het op zijn beurt verkocht aan Acambis.

    Grtz,
    ZEKER
    www.iex.nl/forum/topic.asp?forum=228&...
  6. [verwijderd] 15 maart 2006 07:33
    Glaxo, Gilead, Merck part of team to fight HIV

    Triangle Business Journal - 1:43 PM EST Tuesday
    GlaxoSmithKline, Gilead Sciences Inc., and Merck & Co. have joined an international partnership to increase the number of HIV drugs available to children in Third World countries.
    First Lady Laura Bush on Monday announced a collaborative effort on the part of the U.S. government, pharmaceutical companies and the United Nations to maximize the use of pediatric HIV drugs currently available and to speed up the development of new treatments.

    The project will be part of the President's Emergency Plan for AIDS Relief and will attempt to identify obstacles that prevent or slow the distribution of HIV drugs to children in developing countries.
    Gilead and Merck, which have Triangle operations, and Glaxo, which has co-U.S. headquarters in Research Triangle Park, join a number of large pharmaceutical companies in the initiative, including Abbott Laboratories, Bristol-Myers Squibb, and Pfizer. Generic drug makers involved in the project include Aspen Pharmacare, Aurobindo Pharma, Cipla, Emcure and Ranbaxy.
    Glaxo is working to develop a scored tablet form - or tablets that can be divided into smaller, uniform doses - of its anti-HIV treatments Epivir, Ziagen and Combivir.
    Officials at the World Health Organization and the United Nations Children's Fund claim that access to tablet forms of HIV drugs could be easier to store and distribute in Third World countries and could simplify the process of administering the drugs.
    California-based Gilead operates an office in Durham, and Merck, which is based in Whitehouse Station, N.J., has plans to construct a $300 million vaccine plant in Durham that is expected to employ about 200 workers.
    GlaxoSmithKline (NYSE: GSK) employs about 5,600 Triangle workers.
    www.bizjournals.com/triangle/stories/...
  7. [verwijderd] 31 juli 2006 19:11
    Where are we and where are we going?

    Mymetics has documented the existence of an important three-dimensional molecular mimicry between the gp41 glycoprotein of HIV-1 and the human interleukin-2 (IL-2) cytokine, a mimicry also found in lentiviruses causing AIDS in other animal species. Mymetics has already explored this mimicry over the last four years as starting point for developing a safe HIV-1 candidate vaccine capable of eliciting protective antibodies, while preventing potential harmful cross-reactivities toward host proteins such as the human IL-2 (Mymetics US Patent 6,455,265). We believe that this innovative concept may render vaccines from the 21st century as efficacious as those from the 20th century, in addition to be safer.
    Together with Protein'eXpert S.A., we have succeeded in engineering and producing in bacteria E. Coli the first gp41 generation in September 2003, which forms soluble and stable gp41 trimers that closely resembles the native gp41 found on HIV-1. This first generation of gp41 immunogen is devoid of the cluster I and 2F5/4E10 epitopes, in addition of being mutated in one important IL-2 mimicry area. The design of the first gp41 generation was intended to identify new important epitopes as well as to focus the immune response on possible neutralizing epitopes different from the 2F5/4E10 previously identified by other teams.
    From January to August 2004, the first gp41 generation was tested in rabbits for it's capacity to elicit neutralizing antibodies toward HIV-1. Such antibodies were obtained in large quantities and their neutralizing potential was evaluated by our academic collaborators. Thus, a renowned scientist in the field of transcytosis, Dr. Morgane Bomsel (Cochin Institute, Paris, France), obtained 60% inhibition of HIV-1 transcytosis with primary strains. Sera were also tested in the laboratory of Dr Christiane Moog (Institut Pasteur, Strasbourg, France), a well acclaimed specialist in neutralizing antibodies in the HIV field. In the performed assay, primary T cells infection by primary HIV-1 strains from clade B (Bx-08 and SF-162) and clade C (TV1) were respectively neutralized at 70%, 80% and 90% by low sera dilutions. When total rabbit antibodies were purified from the serum, a neutralizing activity of 80% was obtained with an antibody concentration of 20µg/ml, using three primary HIV-1 strains. These results are similar to those obtained with the 2F5 monoclonal antibody (>90% inhibition), one of the most potent neutralizing antibodies so far identified. Infection of primary human macrophages by primary HIV-1 strains was also strongly inhibited (>90%) with a low antibody concentration (<2µg/ml). These preliminary results were highly encouraging, considering that the first gp41 generation of immunogen did not include the 2F5/4E10 epitopes.
    A second gp41 generation that has included the 2F5 and 4E10 epitopes was obtained in August 2004 and produced on a larger scale in September 2004. However, several technical difficulties were encountered during the production of this antigen. First, these gp41 proteins formed inclusion bodies in bacteria that were difficult to solubilize. Gp41 proteins obtained after denaturation and refolding were forming dimer of trimers instead of the natural trimeric form, as observed with the gp41 1st generation. Despite of this, these new gp41 immunogens were incorporated into liposomes and were well recognized by the 2F5 and 4E10 monoclonal antibodies kindly provided by Dr Wayne Koff (IAVI), which suggest the presence of functional epitopes. Rabbit immunizations with gp41-liposomes have been achieved from Fall 2004 to Winter 2005 and animal sera were tested. Not surprisingly, this gp41 2nd generation did not elicit neutralizing antibodies in rabbits, as we initially expected. When mixed with liposomes, the gp41 2nd generation can form proteo-liposomes that are unstable. Furthermore, gp41 proteins can bind randomly to liposomes with no preferential orientation. In such situation, some key epitopes like the 2F5 may not be properly maintained or presented to the immune system and consequently, these epitopes are ignored or poorly recognized.
    Based on the experience acquired over the past 3 years, we strongly believe that orienting the anchorage of gp41 proteins or gp41-derived peptides onto stable synthetic lipid membranes will better present the antigen to the immune system. Therefore, a 3rd generation of recombinant gp41 proteins was engineered during Winter-Spring 2005, which lead to the conclusion that not all epitopes should be present on the same antigenic structure. In fact, to avoid protein aggregation and to improve the yield of protein production, some epitopes most be taken separately from others on different antigens. This approach offers the main advantage to present key epitopes to the immune system, using different antigens, which should eliminate the problem of epitope immunodominance. Furthermore, we intend to better target the mucosal immune system by a more adequate vaccine delivery: nasal administration and epido-dermis junction using micro-needles.

    In parallel, during Winter-Spring 2005, and in collaboration with Pevion Biotech Ltd. (Switzerland) and Dr. Bomsel from the Cochin Institute in Paris (France) we have formulated the second vaccine component that consists of peptides derived from the conserved proximal membrane region of the gp41 ectodomain. These peptides were grafted in an oriented manner onto biosynthetic stable spheres. Rabbit immunizations were launched from May to November 2005 for targeting the mucosal immune response. Biological samples were analyzed and all rabbits have produced specific antibodies toward the gp41 peptides. More importantly, when these samples were tested into transcytosis assays, most of these vaginal secretions (diluted 10-fold for the assay) containing antibodies that were able to prevent translocation (transcytosis) of primary R5 clades B and C with an efficiency of 80-90%, which is close to what is achieved with human secretions isolated from HIV-resistant women.

    Starting in winter 2006, a pre-clinical trial with the peptide approach on non-human primates (macaques) is scheduled in Beijing (China). We expect these macaques to develop specific antibodies at the mucosal levels over the 6 months vaccination protocol. Following vaccination, macaques should be challenged with viruses to measure the level of protection. In parallel, we are in the process of developing the gp41 4th generation that will combine the best characteristics of the first three generations of gp41 previously synthesized. We plan to launch other pre-clinical trials on macaques in summer 2006 for testing the combined vaccine components, meaning injecting together gp41-derived peptides and recombinant trimeric gp41 proteins, each eliciting different types of antibodies for different anatomical compartments. Clinical lots of gp41 immunogens are planed for late 2006 for toxicology and phamacokinetics evaluations. Human tolerance and immunogenicity of the gp41 immunogens should thereafter take place in a phase I clinical trial in 2007.
    www.mymetics.com/mymetics_pages/techn...
  8. [verwijderd] 6 januari 2007 17:07
    Uit juni 2006.
    Mymetics Announces Encouraging Preclinical Results of the Company's HIV Vaccine Candidate in Non-Human Primates
    Study Confirms Ability of Vaccine Candidate to Elicit Anti-gp41 Antibodies

    NYON, Switzerland, June 21 /PRNewswire-FirstCall/ -- Mymetics Corporation (NASDAQ: MYMX.PK) announced today encouraging, preliminary findings from non- human primate preclinical studies of the Company's HIV-AIDS prophylactic vaccine candidate. Analysis of blood samples taken six weeks post-vaccination with virosome-gp41 peptides have revealed the presence of anti-gp41 antibodies (IgG and IgA), confirming previous data from rabbit models. The immunization protocols will continue through early September 2006 in order to detect the production of secretory IgA antibodies in mucosal tissues, the primary route of infection and a first line of defense against HIV.
    Dr. Sylvain Fleury, Ph.D., Mymetics' Chief Scientific Officer, commented, "At the mid-point of our non-human primate trials, we are greatly encouraged by the results, particularly in the ability to trigger protective antibodies against gp41 independently from gp120, another key target in HIV. Based on the current timeline, we hope to be able to detect the presence of mucosal antibodies by the end of the third quarter, following which we will seek to demonstrate protection against HIV infection in these animal models by the first quarter of 2007. Our ultimate goal is to initiate Phase I human clinical trials by the end of 2007, pending the positive preclinical results."
    Mymetics' vaccine candidate combines the Company's HIV-1 gp41-derived peptide antigen grafted onto biosynthetic spherical lipidic structures called virosomes, which are approved for human use. Previous Company research has demonstrated that virosome-based vaccine technology is able to elicit protective antibodies in various anatomical compartments, which may prevent viral translocation across mucosal tissues and infection of blood cells by different HIV clades (genetic sub-groups). These virosomes mimic the HIV envelope and allow proper viral peptide/protein and epitope orientations, similar to what is found on native HIV.
    Underlying these efforts is Mymetics' key discovery of a fundamental though subtle three-dimensional mimicry between the viral envelope glycoprotein gp41 of HIV-1 and the IL-2 cytokine (Interleukin-2) of the infected host. Mymetics strongly believes that it is crucial to prevent the potential induction of cross-reactivity toward self-proteins, such as IL-2, post-vaccination in order to generate a protective and long-lasting mucosal immune response against HIV-1.
    Mucosal Approach
    Worldwide, over 85% of HIV infections are the result of sexual transmission in which mucosal tissues from the genital and anorectal regions have been exposed to HIV-1 present in semen or secretions. Mymetics is developing a vaccine technology that elicits protective antibodies in various anatomical compartments, such as blood, but most importantly in mucosal tissues within the genital and intestinal tracts, particularly via secretory IgA antibodies.
    Results presented earlier this year at the Keystone Symposium on HIV Pathogenesis have demonstrated that sequential, intranasal immunizations of Mymetics' vaccine candidate in a rabbit model led to a sustained mucosal immune antibody response, both in the vaginal and intestinal tracts, which lasted at least 2 months after the last injection. A similar immune response may be obtained using the intramuscular route only, thereby avoiding the need for a mucosal adjuvant. The Company is currently investigating in non-human primates whether intramuscular injections alone can match the levels of mucosal antibodies achieved following sequential intranasal and intramuscular injections. Final results are expected for September 2006.
    In previous in vitro studies, Mymetics-affiliated researchers demonstrated that mucosal antibodies (vaginal and intestinal) were highly potent in inhibiting transcytosis of laboratory and primary HIV viruses from different clades, including the B clade, common in North & South America and Western Europe, and the C clade, which is found in South Africa, India and parts of China and accounts for more than 60% of cases of HIV infection. The overall inhibition capacity varied from 70% to 95%. In addition, ELISA tests demonstrated that the mucosal antibodies were dominantly constituted of monomeric IgG and dimeric secretory IgA. Vaginal secretions containing antibodies were also very potent in inhibiting primary macrophage infections (>90%). Additional studies will be performed to investigate dendritic and T cell infection.
    Mymetics' HIV Vaccine Program
    Mymetics' innovative AIDS vaccine proposes an approach that could prevent HIV entry at the mucosal level (primary entry: early event) as well as preventing cell infection by HIV (late event). To achieve this goal, Mymetics has combined three important concepts in the vaccine design:
    1- Induction of mucosal and blood antibodies to allow protection in different anatomical compartments and block the early event of HIV translocation at the genito-reproductive and intestine tracts and subsequent infection of target cells underlying the mucosal tissues, thereby preventing HIV entry and spreading in the body.
    2- Focusing the immune response against conserved regions on gp41 that may induce protective antibodies against a broad range of HIV clades. Mymetics is developing vaccines that contain antigens expressing limited immunodominant regions, while immunodistractive regions have been removed or altered without affecting the immunogenicity of the antigen.
    3- Minimal mimicry. In this approach, Mymetics uses a small engineered HIV protein sequence from gp41, which has been deleted of its human protein homologies. The Company's approach is designed to significantly reduce the risk of developing potential autoimmunity on a long-term basis following vaccination.
    Mymetics believes that it is pioneering an innovative and efficient research strategy. Instead of incurring high fixed costs to maintain its own staff and research facilities, Mymetics organizes and manages a network of public and private research teams that it believes are best-in-class, each of which has its own particular focus, while the Company retains all intellectual property rights to the joint research results.
    sev.prnewswire.com/health-care-hospit...
    of
    www.bioportfolio.com/June_06/22_06_20...

    Beetje weird imo, geen vermelding van dit pb op de site:
    www.mymetics.com/mymetics_pages/ir_my...
    Latest Press Release, d.d. 09-03-2006.
  9. [verwijderd] 6 januari 2007 17:08
    Vervolg.

    The innovative Mymetics AIDS preventive vaccine approach
    The majority of HIV vaccine strategies have so far focused on the structural antigens of HIV-1, in particular Env. These Env-based vaccines have induced a protection that was limited to homologous virus challenge or closely related HIV-1 strains, while protection from heterologous virus challenge has proven to be much more difficult to achieve. It has been postulated that past failures to elicit broad neutralizing antibodies with the viral glycoproteins may be due in part to the use of recombinant monomeric gp41, gp120 or gp160 molecules that were improperly folded and did not expose the neutralization epitopes, in addition to having monomeric structures that may differ significantly from the native trimeric glycoproteins found on HIV surface. So far, only five broadly neutralizing HIV-1 reactive mAb have been isolated; two are directed against the gp120 (2G12 and b12), and the other three are directed against the gp41 (2F5, 4E10 and Z13). the 2F5 being the most potent, 4E10 the most broad and Z13 the least efficient.

    Of primary concern in recent efforts to develop an efficient HIV-1 vaccine has been the design of immunogens capable of eliciting neutralizing antibodies (2F5-like) against a wide spectrum of HIV-1 strains. New candidate vaccines based on trimeric glycoproteins gp160, gp140 and gp41 that are closer to the native viral proteins have been designed. However, these artificially produced trimeric forms are usually unstable in solution without detergent or when mixed with adjuvants, and usually contain several immunodominant regions on the same antigens, which may hamper efforts to produce an effective preventive vaccine.
    Mymetics Corp's primary goal is to engineer modified gp41-derived immunogens capable of eliciting a broad antibody response to various HIV-1 clades. To achieve this goal, Mymetics Corp. and its key partners, Dr. Morgane Bomsel (Cochin Institute, Paris, France) and, Protein’eXpert S.A. (Grenoble, France), a company highly specialized in protein production, have developed engineered gp41 HIV peptides and glycoproteins. We have found a way of making stable peptide associations and gp41 trimers, all properly oriented and presented. We propose to develop gp41 immunogens with impaired immunodominant cluster I area that distract the immune system. This loop generates numerous non-neutralizing antibodies that may distract the immune system, in addition to being an important mimicry area for the IL-2 and other human proteins. Therefore, our HIV-1 vaccine approach is based on the use of an engineered stable dimeric and trimeric forms of gp41-derived antigens that closely resembles the native gp41 and capable of focusing the immune response on epitopes that may induce protective antibodies with minimal cross-reactivity toward self-proteins like IL-2 (Mymetics US Patent 6,455,265). Therefore, our candidate vaccine may be considered safer because of the removal of human homologies in the viral antigen. Mymetics has developed four generations of gp41 trimers and the latest one is promising.
    www.mymetics.com/mymetics_pages/more_...

    Possible vaccine approaches
    www.mymetics.com/mymetics_pages/more_...
    ********************************
    Mymetics' HIV-AIDS prophylactic vaccine candidate program combines the Company's HIV-1 gp41-based immunogen expertise with virosome technology developed by Pevion Biotech AG (Switzerland), a spin-off from Berna AG and Bachem AG. Virosome-based vaccines are market-approved, stable lipidic structures that act as carriers for peptides or proteins toward which an immune protection is desired. Virosomes have a high safety profile with few side effects and have already been distributed by Pevion Biotech AG and administered to millions of people around the world.

    Ownership Pevion Biotech by Crucell = 50%
    www.secinfo.com/d11MXs.v1cD9.9.htm
    ************************
    Meer mbt Pevion in go's Pevion-draadje
    www.iex.nl/forum/topic.asp?forum=228&...
9 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 913,25 -0,03%
EUR/USD 1,0870 +0,03%
FTSE 100 8.420,26 -0,22%
Germany40^ 18.716,50 +0,06%
Gold spot 2.415,21 0,00%
NY-Nasdaq Composite 16.685,97 -0,07%

Stijgers

NX FIL...
+8,76%
VIVORY...
+6,12%
Sif Ho...
+4,09%
RENEWI
+3,21%
HEIJMA...
+3,08%

Dalers

Corbion
-3,97%
ADYEN NV
-3,20%
EBUSCO...
-3,00%
SIGNIF...
-2,50%
PROSUS
-2,29%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!